Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | Clinical manufacturing of CAR T-cells

Bruce Levine • 5 Apr 2019
EBMT 2019
Leukemia Lymphoma Multiple Myeloma CAR-T

Bruce Levine, PhD, from the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, highlights the challenges in manufacturing complex cell products in CAR T-cell therapy. This video was recorded at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

More from Bruce Levine

1:26
The impact of COVID-19 on CAR-T therapy
Bruce Levine • 28 May 2020
1:15
CAR-T therapy: where is it going?
Bruce Levine • 28 May 2020
1:20
ISCT 2020: Moving ahead at full speed session - what can delegates look forward to?
Bruce Levine • 28 May 2020
1:00
ISCT 2020: looking forward to advances and emerging technologies in immune-mediated cancer therapy
Bruce Levine • 28 May 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals